1 of the perks I get to enjoy is that on occasion, I get emails from readers all over the world who want to share ideas, discuss philosophy, seek solace, or even tell me stories. I try to reply everything. Today, I’m sharing 1 such investing thesis brought to me by a reader. He’s interested to get this posted, but prefers to remain anonymous. So here goes: Ticker: CHMA Price: $4.41 FD shares outstanding: 74.6 million Market cap: $255 million Cash: $156.8 million Debt: $66.1 million Enterprise value: $164.3 million Chiasma Pharmaceuticals is a small biotech company that has pioneered a novel drug delivery technology they refer to as “Transient Permeability Enhancer” or TPE, which allows for oral delivery of drugs that traditionally had to be given via intramuscular injection due to poor bioavailability.  Earlier this year, the FDA approved Chiasma’s first drug candidate, Mycapssa, validating the technology and launching them into the commercial stage....